Cancer Drug Blockbusters

Published Date: 04/11/2010
Category: Therapies & Markets

Research Report Decription

Sample Pages:

Click here (PDF)

This report’s glimpse into the future reveals a market environment where the new targeted therapies prevail as the future blockbusters, with biological, in particular, commanding substantial sales before the impact of any biosimilar competition in major markets. The pursuit of safe and effective cancer medicines dominates research funding and the sector has more blockbuster products than any other therapy area. There exists a huge variety of cancer treatments, from the widely-used chemotherapeutic agents to the recently-launched, first-in-class cancer vaccine, with many of these treatments achieving blockbuster sales in excess of US$1 billion. However, many existing brands face declining sales due to generic erosion as patents expire, and the rate at which new drugs reach the market is slowing, impacting company revenues.

Key Questions Answered:

• Which companies will have increased their market share by 2016?
• Who will be the new members of the cancer blockbuster club in the future?
• What are the prospects for hormonal therapies?
• To what degree will Sprycel, Tasigna and generic competition affect Novartis’ Gleevec?
• What product extensions did Roche get for Herceptin in 2010?
• Where to next for Pfizer after it suspended development of Sutent in a range of cancers in September 2009?
• How might cheaper generic doxetaxel affect sales of Dendreon’s novel vaccine for CRPC patients?

Paper Highlights:

This report identifies the current oncology blockbuster products and assesses their future market potential, looking at both winners and losers in the competitive landscape to 2016. In addition, it highlights the promising products that, in Espicom’s analysis, will successfully carve out a market share to become the oncology blockbusters of the future. Both current and future marketplaces are analysed from the companies’ perspective, identifying the products on which their relative success or failure rests.

All 21 products featured in this report are also detailed and analysed individually in terms of their current status, mode of action, clinical data, risks associated with their development, expertise of developing/marketing company and the competitive pressures they may face. This analysis is summarised in the form of a unique score that acts as a useful comparative tool and 7-year individual product forecasts are provided to 2016.

Whether you are involved with competitive monitoring, product planning or business development, this new report will provide the facts and insight to fully understand the trends, companies and products which are shaping this critical area of the pharmaceutical industry.